Design for an ipriflavone multicenter european fracture study

Calcified Tissue International

Volumn 61, Issue SUPPL. 1, 1997, Pages

  Reginster, J Y ^a,f   Bufalino, L ^b   Christiansen, C ^c   Devogelaer, J P ^d   Gennari, C ^g   Riis, B J ^c   Roux, C ^e  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Medical Department   (Italy)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Université Paris Descartes   (France)

^f CHU SART TILMAN   (Belgium)

^g NONE

Author keywords

Fracture intervention trial; Ipriflavone; Osteoporotic fractures

Indexed keywords

IPRIFLAVONE;

ADULT; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORPHOMETRICS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIUM; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOFLAVONES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY CONTROL; RADIOIMMUNOASSAY; RESEARCH DESIGN; SPINAL FRACTURES; STATISTICS; TREATMENT OUTCOME;

EID: 0030743422     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900382     Document Type: Conference Paper

References (31)

1. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227-1233
2. Consensus Development Conference (1994) Am J Med 94: 646-650
3. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W (1992) Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 7:633-638
4. WHO Technical Report Series no. 843 (1994)
5. Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Int Med 102:319-324
6. Grady D, Rubin S, Petitti D (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037
7. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 117:1-9
8. Reginster JY (1993) Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 23:223-232
9. Morita I, Sakagushi K, Kurachi T, Murota S (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51:S7-S10
10. Tsuda M, Kitazaki T, Itoh T, Fujita T (1986) The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1:207-212
11. Bonucci E, Ballanti P, Martelli A, Mereto E, Brambilla G, Bianco P, Bufalino L (1992) Ipriflavone inhibits osteoclasts differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 50:314-319
12. Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M (1986) Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci 38:951-958
13. Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987-996
14. Notoya K, Tsukuda R, Yoshida K, Taketomi S (1992) Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture. Calcif Tissue Int 51:S16-S20
15. Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R (1994) Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 55:356-362
16. Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimaragonas A (1995) Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int 56:215-219
17. Ghezzo C, Cadel S, Borelli G, Maiorino M, Civitelli R, Bufalino L, Bongrani S (1996) Ipriflavone does not alter bone apatite cristal structure in adult male rats. Calcif Tissue Int 59:496-499
18. Mazzuoli GF, Agnusdei D, Crepaldi G, Isaia GC, Ortolani S, Passeri M, Bufalino L, Gennari C (1996) Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC Delmas PD (eds) Proceedings of 1996 World Congress on Osteoporosis, Amsterdam, 18-23 May. Elsevier, Amsterdam, The Netherlands pp 281-284
19. Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Serni U, Vecchiet L, Passeri M (1997) Ipriflavone prevents radial bone mass loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int 7:119-125
20. Valente M, Bufalino L, Castiglione GN, D'Angelo R, Mancuso A, Galoppi P, Zichella L (1994) Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377-380
21. Passeri M, Biondi M, Costi D, Dall'Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Mineral Electrolyte Metab 9:137-144
22. Maugeri D, Panebianco P, Motta M, Tropea S, Motta L, Garozzo C, Lomeo E, Sangiorgi GB, Scuderi G, Carozzo M, Cantatore FP, Perpignano G, Ferraraccio A, Ennas F (1994) Ipriflavone treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 19:253-263
23. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82-91
24. Gambacciani M, Spinetti A, Piaggesi L, Cappagli B, Taponeco F, Manetti P, Weiss C, Teti GC, La Commare P, Facchini V (1994) Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists. Bone Miner 26:19-26
25. Agnusdei D, Gennari C, Bufalino L (1995) Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int 5:462-466
26. Genant HK, Wu CY, Van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
27. Smith-Bindam R, Cummings SR, Steiger P, Genant HK (1991) A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 6:25-34
28. Wu CY, Li J, Jergas M, Genant HK (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporosis Int 5:354-370
29. Hansen MA, Hassager C, Overgaard K, Marslew U, Riis BJ, Christiansen C (1990) Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine. J Nucl Med 31:1156-1162
30. Gillings D, Koch G (1991) The application of the principle of intention-to-treat analysis of clinical trials. Drug Inform J 25: 411-424
31. CPMP 22 DOC/FINAL/JAL/SAK (15.12.94). Note for Guidance, Bruxelles